Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

What's fueling the biotech engine—2011 to 2012

Sales in the biologics sector show modest but healthy growth rates for the fourth consecutive year, with cancer drugs garnering the greatest revenues. As the diabetes epidemic grows and innovation of insulins continues, drug companies in that space are moving up in the ranks.

Figure 1: Growth trends in the United States biotech market for biologic drugs (2007–2011).
Figure 2: Top nine categories of biologic drugs in terms of US sales in 2011.
Figure 3: Companies with the top sales of biologic drugs in 2011.
Figure 4: Trends in US sales of mAbs.
Figure 5: Trends in US sales of recombinant hormones.
Figure 6: Trends in US sales of growth factors.
Figure 7: US sales of cytokines and blood factors ($ billions).
Figure 8: US sales of therapeutic enzymes, recombinant vaccines and anticoagulants ($ billions).

References

  1. 1

    IMS Health Top-Line Market Data. <http://www.imshealth.com/portal/site/ims>

  2. 2

    Aggarwal, S. What's fueling the biotech engine-2009–2010. Nat. Biotechnol. 28, 1165–1171 (2010).

    CAS  Article  Google Scholar 

  3. 3

    Aggarwal, S. What's fueling the biotech engine—2008. Nat. Biotechnol. 27, 987–993 (2009).

    CAS  Article  Google Scholar 

  4. 4

    Aggarwal, S. What's fueling the biotech engine—2010 to 2011. Nat. Biotechnol. 29, 1083–1089 (2011).

    CAS  Article  Google Scholar 

  5. 5

    Hamlin, P.A. Is maintenance rituximab now ready for PRIMA-time? Curr. Oncol. Rep. 12, 355–357 (2010).

    Article  Google Scholar 

  6. 6

    Garber, K. Pfizer's JAK inhibitor sails through phase 3 in rheumatoid arthritis. Nat. Biotechnol. 29, 467–468 (2011).

    CAS  Article  Google Scholar 

  7. 7

    Sandborn, W.J. et al. Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. N. Engl. J. Med. 367, 616–624 (2012).

    CAS  Article  Google Scholar 

  8. 8

    van Vollenhoven, R.F. et al. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N. Engl. J. Med. 367, 508–519 (2012).

    CAS  Article  Google Scholar 

  9. 9

    Helwick, C. Bevacizumab beyond progression prolongs survival in metastatic colorectal cancer. The ASCO Post 3 (15 July 2012).

  10. 10

    Heitz, F. et al. Bevacizumab in the treatment of ovarian cancer. Adv. Ther. 29, 723–735 (2012).

    CAS  Article  Google Scholar 

  11. 11

    Bach, P.B., Saltz, L.B. and Wittes, R.E., “In cancer care, costs matters.” NY Times, 14 October 2012

    Google Scholar 

  12. 12

    de Claro, R.A. et al. U.S. Food and Drug Administration approval summary: Brentuximab Vedotin for the treatment of relapsed Hodgkin lymphoma or relapsed systemic anaplastic large cell lymphoma. Clin. Cancer Res. 18, 5845–5849 (2012).

    CAS  Article  Google Scholar 

  13. 13

    Zinman, B. et al. Insulin degludec, an ultra-long-acting basal insulin, once a day or three times a week versus insulin glargine once a day in patients with type 2 diabetes: a 16-week, randomised, open-label, phase 2 trial. Lancet 377, 924–931 (2011).

    CAS  Article  Google Scholar 

  14. 14

    Collins, A.J. ESRD Payment Policy Changes: The New “Bundled” Dialysis Prospective Payment System in the United States (US Renal Data System, 2012). <http://www.usrds.org/2012/pres/USDialysisBundle_impact_NKFCM2012.pdf>

  15. 15

    Aggarwal, S. Access, Uptake and Utilization Management of Multiple Sclerosis Products in the United States. Abstract PND72, presented at15th Annual European Congress, November 3–7, 2012, Berlin, Germany.

  16. 16

    Hayes, E. Dendreon readies for next Provenge hurdles: supply and reimbursement. The Pink Sheet Daily 71 <http://www.elsevierbi.com/publications/the-pink-sheet/72/018/dendreon-readies-for-next-provenge-hurdles-supply-and-reimbursement> (3 May 2010).

  17. 17

    Aggarwal, S. Targeted cancer therapies. Nat. Rev. Drug Discov. 9, 427–428 (2010).

    CAS  Article  Google Scholar 

  18. 18

    Polonsky, K.S. The past 200 years in diabetes. N. Engl. J. Med. 367, 1332–1340 (2012).

    CAS  Article  Google Scholar 

  19. 19

    Aggarwal, S. Impact of 2009–2011 global health care reforms on pricing, access and health outcomes strategy. Podium Presentation UT2 presented at International Society for Pharmacoeconomics and Outcomes Research 17th Annual International Meeting, June 2–6, 2012, Washington, DC, USA.

Download references

Acknowledgements

SA thanks American Society of Clinical Oncology (ASCO), American College of Rheumatology (ACR), American Association of Liver Diseases (AASLD), American Heart Association (AHA), American Society of Hematology (ASH) and Biotechnology Industry Association (BIO) for providing support for this article.

Author information

Affiliations

Authors

Corresponding author

Correspondence to Saurabh (Rob) Aggarwal.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Aggarwal, S. What's fueling the biotech engine—2011 to 2012. Nat Biotechnol 30, 1191–1197 (2012). https://doi.org/10.1038/nbt.2437

Download citation

Further reading

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing